News & Videos - INSMED INC.

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Jan. 3, 2025 BRIDGEWATER, N.J. , Jan. 3, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 19 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were...

Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire BRIDGEWATER, N.J., Jan. 2, 2025 BRIDGEWATER, N.J. , Jan. 2, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Dec. 6, 2024 BRIDGEWATER, N.J. , Dec. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 30 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were...

Insmed To Present at December 2024 Investor Conferences PR Newswire BRIDGEWATER, N.J., Dec. 2, 2024 BRIDGEWATER, N.J. , Dec. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Evercore ISI HealthCONx Conference in Coral Gables, Florida , on...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Nov. 7, 2024 BRIDGEWATER, N.J. , Nov. 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 27 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were...

Insmed To Present at November 2024 Investor Conferences PR Newswire BRIDGEWATER, N.J., Nov. 6, 2024 BRIDGEWATER, N.J. , Nov. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference in Boston on...

Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update PR Newswire BRIDGEWATER, N.J., Oct. 31, 2024 —ARIKAYCE ® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023— —NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expected in Mid-2025— —Expanded U.S. Sales Force is Now Fully...

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List PR Newswire BRIDGEWATER, N.J., Oct. 24, 2024 —Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J. , Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science 's...

Insmed Unites Across Communities Around the World During Third Annual Global Day of Good PR Newswire BRIDGEWATER, N.J., Oct. 23, 2024 Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe , and Japan BRIDGEWATER, N.J. , Oct. 23, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients...

Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024 PR Newswire BRIDGEWATER, N.J., Oct. 17, 2024 BRIDGEWATER, N.J. , Oct. 17, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its third-quarter 2024 financial results on Thursday, October 31, 2024....

New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results PR Newswire BRIDGEWATER, N.J., Oct. 8, 2024 —Data Presented at the CHEST 2024 Annual Meeting— BRIDGEWATER, N.J. , Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Oct. 4, 2024 BRIDGEWATER, N.J. , Oct. 4, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 52 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Sept. 6, 2024 BRIDGEWATER, N.J. , Sept. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 60 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards...

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update PR Newswire BRIDGEWATER, N.J., Aug. 8, 2024 —ARIKAYCE ® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023— —U.S. Launch Readiness for Brensocatib in Bronchiectasis Remains on Track with NDA Submission Expected in the Fourth Quarter of 2024— —Primary Endpoint for ENCORE Study of ARIKAYCE in...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Aug. 2, 2024 BRIDGEWATER, N.J. , Aug. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 97 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and...

Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024 PR Newswire BRIDGEWATER, N.J., July 29, 2024 BRIDGEWATER, N.J. , July 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second-quarter 2024 financial results on Thursday, August 8, 2024. Insmed management will host a conference call for...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., July 5, 2024 BRIDGEWATER, N.J. , July 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and...

Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference PR Newswire BRIDGEWATER, N.J., July 3, 2024 —New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo— —Additional Exploratory Endpoints to be Presented, Including FVC and Patient-Reported BEST Score— BRIDGEWATER, N.J. , July 3, 2024 /PRNewswire/ -- Insmed...

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 PR Newswire BRIDGEWATER, N.J., June 27, 2024 BRIDGEWATER, N.J. , June 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has called all $225 million aggregate principal amount of its outstanding 1.75% Convertible Senior Notes Due 2025 (the "Notes")...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., June 7, 2024 BRIDGEWATER, N.J. , June 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 15 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and...